Clinical Trials

Drugmaker holds kick-off meeting with CRO regarding upcoming Liprostin trial

Published in Medical Letter on the CDC and FDA, March 12th, 2006

Endovasc, Inc., (EVSC), announced that the company has met with their project team at Synergos, the clinical research organization (CRO) that will oversee its upcoming Liprostin clinical trial to finalize the protocol for U.S. Food & Drug Administration submission.

Additionally, Synergos reviewed a list of clinical sites for the trial and will begin contacting the sites to determine their willingness to join the study and assess potential enrollment.

"Based on the successful completion of a phase II trial, further studies of Liprostin are warranted. We are extremely pleased to be moving forward with the clinical-development program for Liprostin and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-03-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry